Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.

L Shiffman, Mitchell; Rustgi, Vinod; Bennett, Michael; Forns, Xavier; Asselah, Tarik; Planas Vila, Ramon; Liu, Li; Pedrosa, Marcos; Moller, Jonathan; Reau, Nancy

doi:10.1038/ajg.2016.108

Public

Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.

Shared by NobleBlocks on Jun 1, 2016 • 12:00 AM UTC

Authors:

Mitchell L Shiffman

Vinod Rustgi

Michael Bennett

Abstract

OBJECTIVES: Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability of antiviral drugs, particularly relevant in patients with advanced liver disease caused by chronic hepatitis C virus (HCV) infection seeking therapy. Using integrated dat...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!